Skip to content
Review

Stem cell–based regenerative therapies for non-ischemic cardiomyopathy: mechanistic insights, clinical evidence, and future directions

Jul 2026 · Molecular Biology Reports · Vol 53 · 0 citations · 101 references
Medicine

TL;DR

This review synthesizes current evidence, highlights translational challenges, and explores emerging directions, including biomaterial-assisted delivery and precision medicine-based patient stratification, which may enable stem cell therapies to become a viable adjunct in managing NICM.

View source

Similar papers

Review Open access Jul 2026

Cell-Based Therapies for Cardiac and Vascular Regeneration in Cardiovascular Disease: Recent Advances, Translational Barriers, and Future Directions

This review examines the full range of cell-based strategies studied to date, the clinical trial evidence, the barriers to progress, and what engineered vesicles, bioengineered tissue constructs, gene editing, and improved trial design might offer.

Sayan Paul, Raj Wasnik, Ranjith Kumavath et al. · 0 citations
Review Open access Aug 2026

Stem Cell-Derived Cardiac and Conduction System Cells for Heart Regeneration and Repair: Current Progress and Future Directions.

Cardiovascular disease remains the leading cause of global mortality, in part because the heart has limited regenerative capacity. Human-induced pluripotent stem cells (hiPSCs) offer a scalable, patient-specific platform for modeling heart disease, advancing drug discovery, and developing regenerative therapies. This r...

Berra Koskulu, Tabish Ali, Ilkin Tetik-Altintop et al. · 0 citations
Review Open access Sep 2026

Rethinking Stem Cell Therapy for Cardiomyopathy in View of Mammalian Cardiac Regeneration Limits

Stem cell transplantation represents a promising approach to regenerative medical therapies for many disorders, including neurodegenerative, rheumatologic, digestive, orthopedic, hematologic and cardiovascular diseases. In the case of stem cell therapy for ischemic cardiomyopathy, this promise has been blunted by a lac...

M. Klegerman · 0 citations
Review Open access Aug 2026

Clinical landscape of human pluripotent stem cell-derived cardiomyocyte therapy.

The pathophysiological rationale for cell-based therapy in heart failure with reduced ejection fraction is summarized, and the preclinical foundations of distinct hPSC-derived product formats are examined, including cell suspensions, epicardial sheets, engineered heart muscle, and cardiac spheroids, each with distinct...

Byron W H Mui, E. Neofytou, Joseph C. Wu · 0 citations
Review Open access Sep 2026

Human iPSC models of myocardial infarction: From injury to repair and therapeutic discovery.

Myocardial infarction (MI) remains a leading cause of death worldwide, and therapies that limit injury, promote repair, and restore cardiac function remain limited. Human induced pluripotent stem cells (hiPSCs) provide a renewable source of patient-specific cardiac cells and have enabled the development of increasingly...

Benjamin B. Johnson, C. Mummery, Richard P. Davis · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.